One of the major challenges in the treatment of the most common subtype of breast cancer (hormone receptor positive, HR+) is the emergence of resistance. In new research published today in Science Advances, Boston Children’s Hospital researchers and colleagues have discovered a new driver of resistance in this cancer, introducing a new direction for early diagnosis of the resistant cancer cells, and a possible path to target them.

A protein that’s essential to every cell’s ability to turn off unnecessary genes is well known for its key function of compacting genes and its connection to cancer when it undergoes mutation. But until now, scientists weren’t quite sure how the protein gets where it needs to go to keep genes bound up so they aren’t activated. In a new study, researchers found that this protein, called linker histone H1, initially flits around inside a cell with no clear aim even in the presence of its target: a nucleosome containing spooled-up segments of DNA. H1 binds directly to two DNA strands sticking out from the nucleosome, but struggles to bind to the nucleosome itself until a chaperone protein escorts it there.

BETHESDA, MD – The Biophysical Society is pleased to announce that Kandice Tanner, of the National Cancer Institute, National Institutes of Health, USA, has been named recipients of the 2027 Michael and Kate Bárány Award. Tanner will be honored at the Society’s 71st Annual Meeting, being held in Philadelphia, Pennsylvania from February 20-24, 2027.

Researchers at the Francis Crick Institute, King’s College London and Complutense University of Madrid have shown that γδ T cells use adaptive immune receptors to drive rapid, innate-like responses to tissue stress, inflammation and cancer.